Physician profile
James Monroe Vaught
NPI 1124041371
$2,929.49
in general payments reported to CMS, 2019-2025
18 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $46.78 · 2021: $396 · 2022: $228 · 2023: $1,270 · 2024: $539 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078 · Entertainment: $63.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.70 |
| Entertainment | $63.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $907.76 | 2023 | |
| Coopervision INC. | $363.33 | 2019-2024 | Myday Contact Lens |
| Optos, INC. | $317.84 | 2021-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $276.51 | 2024-2025 | Omni Surgical System, Tearcare System |
| Lkc Technologies, INC. | $187.08 | 2024-2025 | |
| Glaukos Corporation | $162.55 | 2023 | |
| Bausch & Lomb Americas INC. | $122.30 | 2024 | Miebo, Xiidra |
| Horizon Therapeutics Plc | $115.74 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.75 | 2021 | |
| Sun Pharmaceutical Industries INC. | $60.30 | 2022-2023 | Xelpros, Cequa |
| Oyster Point Pharma, INC. | $59.51 | 2022-2023 | Tyrvaya |
| Alcon Vision LLC | $55.18 | 2020-2025 | Tryptyr |
| Johnson & Johnson Vision Care, INC. | $52.03 | 2022 | |
| Dompe US, INC. | $49.11 | 2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $37.32 | 2025 | Atlas Corneal Topography System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.86 | 2020-2021 | |
| Abbvie INC. | $19.42 | 2023 | Durysta |
| Novartis Pharmaceuticals Corporation | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Vaught listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.